CAMBRIDGE, Mass.--(BUSINESS WIRE)--Imara Inc., a clinical stage biopharmaceutical company, today announced that its Chief Executive Officer, Rahul Ballal, Ph.D., will present at the 7th Annual Sickle Cell Disease Therapeutic Conference on Sept. 13 in New York City. Dr. Ballal’s presentation is scheduled for 3:30 p.m. ET during the company presentations portion of the conference, which is being held at the Park Central Hotel.
Earlier this year, Imara dosed the first patient in its ongoing Phase 2a clinical trial of IMR-687 in adult patients with sickle cell disease. IMR-687 is an oral therapy for once-daily dosing to address both the underlying red and white blood cell pathologies associated with the disease. Interim data from the trial is expected in the fourth quarter of 2018.
The Annual Sickle Cell Disease Therapeutics Conference is a forum to discuss the latest advancements and future trends for treating patients with sickle cell disease. Conference attendees will hear presentations from clinical-stage companies, key opinion leaders, patients, policy makers, and healthcare analysts.
About Sickle Cell Disease
Sickle cell disease is a rare, genetically inherited condition that alters hemoglobin, the protein in red blood cells that transports oxygen throughout the body. The altered hemoglobin distorts red blood cells into a sickle, or crescent, shape. Painful episodes can occur when sickled red blood cells, which are stiff and inflexible, get stuck in small blood vessels. These episodes deprive tissues and organs of oxygen-rich blood and can lead to vaso-occlusive crisis (VOC), acute chest syndrome (ACS), and permanent damage to organs including the liver, spleen, kidney and brain.
Imara Inc., is dedicated to developing novel therapeutics for patients with sickle cell disease and other hemoglobinopathies. Imara is currently developing IMR-687, a highly selective, potent small molecule inhibitor of PDE9, to treat patients with sickle cell disease. IMR-687 was specifically designed to treat patients with sickle cell disease by both reducing red blood cell sickling and blockage of blood vessels that are underlying causes of the pathology of sickle cell disease. The company was launched out of orphan drug accelerator Cydan Development with financing from life science investors NEA, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments.